Cited 2 times in
다제내성 결핵의 진단과 치료
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강영애 | - |
dc.date.accessioned | 2015-01-06T16:26:55Z | - |
dc.date.available | 2015-01-06T16:26:55Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1975-8456 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/98124 | - |
dc.description.abstract | Multidrug-resistant tuberculosis (MDR-TB) is a great public health concern worldwide. MDR-TB denotes bacillary resistance to at least isoniazid and rifampicin. Extensively drug-resistant tuberculosis (XDR-TB) is MDR-TB with additional bacillary resistance to any fluoroquinolone and at least one second-line injectable drug. The treatment of MDR-TB requires prolonged administration of a toxic second line anti-tuberculosis drug and generally has poor outcomes. XDR-TB requires more complex treatment and has higher mortality. MDR- and XDR-TB arise because of inadequate or interrupted administration of first-line treatment and can be transmitted in the community. Thus, prevention of the emergence of resistance is the first principle in the management of MDR/XDR-TB. To prevent the emergence of drug resistance and transmission of MDR/XDR-TB, the adequate prescription of an anti-TB drug by a physician and good adherence of patients are essential. In addition, rapid diagnosis of drug resistance using molecular tests such as a line probe assay and Xpert MTB/RIF and the programmatic management of MDR/XDR-TB by designing an effective regimen using available drugs (a newer generation of fluoroquinolone, second-line injectable drugs, second-line oral drugs, and pyrazinamide) based on a guideline are an important strategy for controlling MDR/XDR TB. Despite the long duration of treatment, the treatment success rate of MDR-TB for patients who started treatment in 2009 has been 48% according to the World Health Organization. Thus, to improve the treatment outcomes of MDR/XDR-TB, new drug development is necessary. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 27~33 | - |
dc.language | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | - |
dc.publisher | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | - |
dc.relation.isPartOf | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | 다제내성 결핵의 진단과 치료 | - |
dc.title.alternative | Diagnosis and treatment of multidrug-resistant tuberculosis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | 강영애 | - |
dc.identifier.doi | 10.5124/jkma.2014.57.1.27 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00057 | - |
dc.relation.journalcode | J01833 | - |
dc.identifier.eissn | 2093-5951 | - |
dc.subject.keyword | Resistance | - |
dc.subject.keyword | Multidrug-resistant tuberculosis | - |
dc.subject.keyword | Diagnosis | - |
dc.subject.keyword | Therapeutics | - |
dc.contributor.alternativeName | Kang, Young Ae | - |
dc.contributor.affiliatedAuthor | Kang, Young Ae | - |
dc.citation.volume | 57 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 27 | - |
dc.citation.endPage | 33 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, Vol.57(1) : 27-33, 2014 | - |
dc.identifier.rimsid | 54904 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.